Role of Pharmacogenetics in Pharmacovigilance

Pharmacovigilance information is most important and has been involved in the summary of product characteristics (SPC) of medications since the turn of the century. Both newly launched medications and those that have a strong market presence rely on pharmacovigilance to help assure patient safety. Adverse events occur after post-marketing if pharmacovigilance reporting is not implemented or enforced for clinical studies. Precisely, it is estimated that between 90% and 100% of adverse events associated with currently available drugs are not reported. As a result, identifying drug safety issues in people with severe comorbidities and complicated conditions is very difficult. Because conventional doses of pharmacological drugs are utilised to treat each patient in populations without these concerns, a complete awareness of potential difficulties and contraindications associated with genome in the population is inadequate. Therefore, pharmacogenetics is a cutting-edge technology that can help to solve these challenges. This chapter discusses pharmacovigilance science, pharmacogenetics, and the importance of pharmacogenetics in adverse drug reactions (ADRs), patient care, and clinical trials. Furthermore, this chapter discusses current pharmacogenetics issues.